CPP has a worldwide population prevalence of 15% in female population between 18 and 50 years and in 61% of cases the etiology is unexplained. Labeling pelvic pain patients with single pathologic diagnoses such as PCS may hinder treatment efforts; however, a prevalence estimated around 30% of PCS in CPP patients has been demonstrated [17].
The pathogenesis of PCS is still unclear, but it has been demonstrated its multifactorial nature. Pregnancy hyper flow venous condition, in terms of gonadal and pelvic plexus dilated, due to estrogen level vasodilator effects could one of the pathogenetic factor involved. A main role, in addition, is related to a valve incompetence development and/or stenosis/obstruction onset of the draining veins [18]. The type 1 Greiner’s classification PCS treated in our study, that is a non-obstructive left ovarian vein insufficiency and reflux, is the most common pathophysiological cause with a prevalence of more than 50% of cases. In 2021 Meissner et al. proposed the Symptoms-Varices-Pathophysiology (SVP) classification of pelvic venous disorders: however, its effective role in determining treatment has still to be demonstrated [19]. A novel PCS management strategy proposed an association between a simple screening tool - the PCS score - that gynecologists and primary care physicians could use, and an accurate noninvasive imaging; this synergy, also used in our study, seems to improve the PCS diagnosis and successful rate treatment [14].
A non-invasive imaging study is mandatory in PCS management strategy, primarily to confirm the clinical suspect of PCS and secondly to exclude other CPP causes [17]. Ultrasound (US), both transabdominal and transvaginal, with colour Doppler imaging and Doppler spectral analysis should be used in PCS diagnosis. A dilated and tortuous pelvic vein (diameter > 6 mm), a slow blood flow (< 3cm/s) or reversal caudal flow, a dilated arcuate veins and polycystic changes in the ovaries are the ultrasound diagnostic criteria for PCS diagnosis [20]. MRI represent the first line of investigation, providing better imaging of the many causes of CPP and, due to the patient young age, should be preferred to Computed Tomography (CT) given the absence of ionizing radiation. MRI has shown a sensitivity and specificity of 88% and 67%, respectively, in demonstration of ovarian veins congestion. However, CT and MRI studies are both performed in supine position, thus being able to underestimate venous dilation compared to US and phlebography where provocative maneuvers could be employed. In our cases, a prior MRI study with demonstration of pelvic venous congestion for ovarian veins and MR angiography sequence with detection of vein dilatation and reflux was mandatory [21]. Catheter phlebography still remains the gold standard for PCS diagnosis, but its diagnostic role is reserved only in cases when noninvasive studies are inconclusive [22].
PCS treatments proposed and used in time are multiple and include conservative, psychological, medical, surgical and endovascular options, both in isolation and in combination. An RCT comparing combined hormone suppression and psychotherapy experienced sustained CPP relief with a > 50% reduction 262 in pain score [23]. A medical therapy, alone or in combination with other treatment, didn’t demonstrated a superior efficacy than another but only an increase of adverse symptoms if used in a long-term setting [24]. Surgical treatments include different alternatives including a mini-invasive laparoscopic approach for ovarian veins ligation to a more invasive one as hysterectomy and/or oophorectomy. Only one study published by Gargiulo et al. demonstrated an extraordinary 100% symptoms relief in 23 women treated with a laparoscopic ovarian vein ligation treatment [25]. Finally, hysterectomy, proposed when all other treatments have failed, showed a 22–33% of failure rate in clinical symptoms resolution [26].
Endovascular management of PCS is recommended with a level 2B evidence by the Society of Vascular Surgery: “We suggest treatment of pelvic congestion syndrome and pelvic varices with coil embolization, plugs, or trans-catheter sclerotherapy, used alone or together” [27]. Our study confirms the actual literature about the difference rate between technical success (almost always described above 95%) and clinical success (usually between 58% and 100%), regardless of the embolic agent. To date, there have not been any randomized study comparing clinical success using different embolic agents for PCS endovascular treatment. The choice of embolic agent is generally operator dependent with no different outcome described with use of a specific agent [17]. Moreover, such a high technical success with a low complication rate allows us to conclude that endovascular techniques are safe and effective in PCS syndrome tretment.
Clinical outcome is in line with previous literature and it could be considered as overall positive. 90% of patients showed a clinical improvement with 46% of patients having complete resolution of symptoms; in only 3 patients (9.3%), endovascular treatment did not improve symptoms. A recent meta-analysis demonstrated a short-term outcome similar to our study, showing a clinical improvement in 88% of patients and a 6–32% of patients that not experienced any symptom relief [28]. Another comprehensive review in 2018 stated that of the 1308 patients included in the study about 75% reported an early symptoms relief after embolization [29].
CPP and other clinical condition of the pelvic floor (i.e., fecal incontinence, organ prolapse, etc…) are closely associated with disfunction of the pelvic floor musculature PFM, so that sEMG could be a useful tool to assess patients’ clinical conditions [11]. In our study, the baseline value of the latency of p40 response and P1-N1 signal amplitude confirm that a slight muscular hypertonia is associated with CPP due to PCS; however, these values after PCS endovascular treatment point out that this correlation, is not directly connected with venous insufficiency, but there are subtle other pathologies related that should be studied further. The R1 latency of the anal reflex comparison show no difference between pre and after treatment; this type of evaluation is directly related with neuronal impairment that is highlighted in only one patient. The results obtained prove that sEMG can reveal alterations in the PFM electrophysiology associated with CPP related to PCS and provide clinicians with objective information that can help them to better evaluate CPP patients’ condition, thus allowing more efficient management of this complex syndrome. Future studies of PCS-related pelvic pain should also evaluate central mediators of vascular tone, perhaps by employing biofeedback or stress reduction. Anxiety and depression in this group of women has long been recognized with much debate as to whether this cause or effect. Farquhar et al. postulated that in a population of PCS patients, only women on combined hormone suppression and psychotherapy experienced sustained CPP relief, pointing out that overlapping neurological and hormonal factors can influence pain symptom expression [23].
Even though the sample size was homogenous, our study has several limitations. First, the sample size studied was small. Second, the evaluation only of patients with a type 1 Greiner’s classification PCS, makes the population more homogeneous, ruling out patients with type 2 and 3 of PCS syndrome, that asses more than 40% of patients with PCS. Third, all patients were recruited by only one interventional radiology center that could bring a selection bias. Last, the absence of a comparison healthy population studied with sEMG. However, given the absence in literature of a randomized controlled trials on management and treatment strategy of PCS with also sEMG study of PFM, our data may provide a reference for a future trial.